Methods and substances for prevention and treatment of neurodegenerative diseases
The present invention provides compositions and methods for the treatment of neurological disorders. In particular, the present invention can be used for treating and/or preventing the symptoms and/or comorbidities of neurodegenerative conditions, diseases or disorders, such as, for example, Alzheimer's and Parkinson's disease.
1. A method for treating a neurodegenerative disease and a comorbidity, wherein said method comprises administering to a subject in need of such treatment an effective amount of a mannosylerythritol lipid (MEL),
wherein said neurodegenerative disease is Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS), and said comorbidity is a microbial infection.
2. The method according to claim 1 , wherein said MEL is the only active ingredient administered to the subject.
3. The method according to claim 1 , wherein said MEL is administered to the subject via a route of administration that is oral, inhalation, parenteral administration including intravenous, subcutaneous, topical, transdermal, intradermal, transmucosal, intraperitoneal, intramuscular, intracapsular, intraorbital, intracardiac, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intracisternal injection, infusion, and/or electroporation.
4. The method according to claim 3 , wherein said MEL is administered to the subject orally.
5. The method according to claim 1 , wherein said MEL is administered with a biosurfactant other than MEL.
6. The method according to claim 1 , wherein the amount of said MEL is at or above critical micelle concentration (CMC) but below chronic toxicity concentration.
7. The method according to claim 6 , wherein the amount of said MEL is 0.1 to 500 mg/kg of the subject's body weight.
8. The method according to claim 7 , wherein the amount of said MEL is 1 to 50 mg/kg of the subject's body weight.
9. The method according to claim 1 , wherein said MEL is administered to the subject once daily.
10. The method according to claim 1 , wherein said MEL comprises MEL-C and/or MEL-D.
11. The method according to claim 1 , wherein said microbial infection is caused by herpes simplex virus, Epstein-Barr virus, cytomegalovirus, varicella zoster virus, influenza virus A, coxsackie virus, echo virus, or coronavirus.
12. A method of treating amyotrophic lateral sclerosis, wherein said method comprises administering to a subject in need of such treatment an effective amount of at least two biosurfactants selected from the group consisting of a sophorolipid, a rhamnolipid, and a mannosylerythritol lipid.